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ABSTRACT
2-Oxoglutarate dehydrogenase (OGDH) of the tricarboxylic acid (TCA) cycle is often 
implied to be inactive in cancer, but this was not experimentally tested. We addressed 
the question through specific inhibition of OGDH by succinyl phosphonate (SP). SP 
action on different cancer cells was investigated using indicators of cellular viability 
and reactive oxygen species (ROS), metabolic profiling and transcriptomics. Relative 
sensitivity of various cancer cells to SP changed with increasing SP exposure and could 
differ in the ATP- and NAD(P)H-based assays. Glioblastoma responses to SP revealed 
metabolic sub-types increasing or decreasing cellular ATP/NAD(P)H ratio under OGDH 
inhibition. Cancer cell homeostasis was perturbed also when viability indicators were SP-
resistant, e.g. in U87 and N2A cells. The transcriptomics database analysis showed that 
the SP-sensitive cells, such as A549 and T98G, exhibit the lowest expression of OGDH 
compared to other TCA cycle enzymes, associated with higher expression of affiliated 
pathways utilizing 2-oxoglutarate. Metabolic profiling confirmed the dependence 
of cellular SP reactivity on cell-specific expression of the pathways. Thus, oxidative 
decarboxylation of 2-oxoglutarate is significant for the interdependent homeostasis of 
NAD(P)H, ATP, ROS and key metabolites in various cancer cells. Assessment of cell-
specific responses to OGDH inhibition is of diagnostic value for anticancer strategies.
INTRODUCTION
Increased thiamin transport in cancer cells 
emphasizes the role of thiamin in cancer cell metabolism 
[1, 2]. However, the significance of the function of the 
thiamin diphosphate (ThDP)-dependent enzymes of 
central metabolism in cancer has not been fully clarified. 
The isoform of ThDP-dependent transketolase, TKTL1, 
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overexpressed in tumors, has long been believed to 
increase ribose-5-phosphate and NADPH required for 
intense proliferation [3-6], but turned out to be catalytically 
incompetent [7, 8]. Independent cellular studies failed 
to establish a correlation between the over-expression 
of TKTL1 or transketolase activity and proliferation 
of cancer cells [9, 10]. The ThDP-dependent pyruvate 
dehydrogenase (PDH) is often supposed to be down-
regulated in cancer due to phosphorylation [3-5, 11, 12] 
under the control of the tumor regulators Myc and HIF-1 
[13, 14]. In line with these findings, an inhibitor of the 
PDH kinase, dichloroacetate, has been shown to negatively 
affect tumor growth, which correlated with PDH activation 
[15-17]. However, our recent study revealed that active 
PDH is required for viability of certain glioblastoma 
cells, although the metabolic impact of PDH may 
significantly vary between different types of glioblastoma 
cells [18]. As a result, the increased thiamin uptake by 
tumors heightens questions regarding the significance 
for cancer cells of the third ThDP-dependent enzyme 
of central metabolism, 2-oxoglutarate dehydrogenase 
(OGDH). Although this multi-enzyme complex is known 
to be an essential regulatory point in the TCA cycle, 
controlling the glutamine and glutamate metabolism 
and limiting the metabolic flux through the cycle under 
a number of experimental settings [19-22], the OGDH-
involving part of the TCA cycle from isocitrate to malate 
is often considered to be switched off in tumors. This is 
thought to occur due to the loss-of-function mutations of 
succinate dehydrogenase and fumarate hydratase [23, 24] 
downstream of OGDH and gain-of-function mutations 
of the non-TCA cycle isocitrate dehydrogenase isoforms 
1 and 2, reducing the OGDH substrate 2-oxoglutarate 
to 2-hydroxyglutarate [11, 25, 26]. Interestingly, a 
catalytically inactive analog of lipoic acid, currently in 
clinical trials, induced cancer cell death concomitant with 
inhibition of the mitochondrial PDH and OGDH complex 
[27-29]. However, neither a specific contribution of PDH 
and OGDH, nor a potential involvement of other lipoate-
reactive systems [30, 31], including the thioredoxin system 
[32, 33], which is a known target of anti-cancer therapies 
[34], can be resolved using the lipoic acid analog. The 
lack of specific knowledge on the role of OGDH in cancer 
metabolism and the recent development of the OGDH 
inhibitors selectively targeting the enzyme in vivo [20-
22], prompted us to study the role of OGDH in cancer cell 
viability using the phosphonate analog of 2-oxoglutarate, 
succinyl phosphonate (SP). Binding to the enzyme as a 
tight transition-state analog [35, 36], SP inhibits OGDH, 
the first rate-limiting component of the mitochondrial 
multi-enzyme complex of oxidative decarboxylation of 
2-oxoglutarate, in a highly selective and efficient manner. 
This was demonstrated using different approaches in a 
number of in vivo and cellular (in situ) systems [20, 22]. 
Given these properties, application of SP to cells aids our 
understanding of pathophysiological mechanisms upon 
perturbation of mitochondrial oxidation of 2-oxoglutarate. 
Taking into account the great variety and plasticity 
amongst tumor cells [37] and current evidence that cancer 
cells retain functional mitochondria and the capacity for 
oxidative phosphorylation in spite of the Warburg effect 
[12, 38], we screened the reactivity to SP of a number of 
cell lines with different levels of malignancy, including 
cells derived from the most common and malignant brain 
tumor, glioblastoma multiforme [39, 40]. An essential 
conclusion of this part of our study is that in many types 
of malignant cells including glioblastoma cells which 
frequently possess mutations of the TCA cycle enzymes 
up- and downstream of OGDH, the TCA cycle has a 
functional OGDH complex and is not interrupted at the 
isocitrate dehydrogenase step. In addition to different 
viability indicators, we used metabolic profiling and 
transcriptomics data deposited in the Gene Expression 
Omnibus (GEO) database. The complementary approaches 
enabled us to identify biochemical network, contributing 
to the cell-specific impact of OGDH inhibition on 
viability. The gained knowledge on molecular mechanisms 
of metabolic heterogeneity of cancer cells may be further 
employed to more efficiently fight tumorigenicity and drug 
resistance in vivo.
RESULTS
SP negatively affects viability of cancer cells as 
revealed by an NAD(P)H-dependent assay
Figure 1 shows a dose-dependent response of 
cancer cell lines to treatment with SP in the assay of 
cellular NAD(P)H-dependent reductase activity with a 
tetrazolium dye (MTT), which is used as an indicator of 
cellular viability. The activity is proportional to cellular 
reducing potential expressed as the level of cellular 
NAD(P)H, owing to which we will subsequently refer 
to the assay as estimating cellular NAD(P)H levels. For 
comparison of human cancer and non-cancer cells, also 
the SP action on primary human skin fibroblasts (HSF) 
is shown in Figure 1A. The data indicate that some of 
the human cancer cells, such as MOGGCCM, A549 and 
T98G, possess a reactivity towards SP which is similar 
to non-transformed human cells, where OGDH belongs 
to the central metabolism (HSF, Figure 1A). To compare 
SP reactivity of transformed and non-transformed cells 
from neural tissue, we included data from transformed cell 
lines from rodents (glioma C6 and neuroblastoma N2A), 
as normal human neurons and glial cells are not available. 
In particular, as seen from Figure 1C, NAD(P)H levels 
of rat astrocytes are significantly decreased by SP already 
after a short (5 h) exposure. During this time, glioblastoma 
cell lines of either human or rodent origin are not affected 
even in the minimal medium (Figure 3C). Worth noting, 
the decrease in the reducing potential of astrocytes 
was not accompanied by any comparable change in 
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cellular protein. When the NAD(P)H level of astrocytes 
decreased more than 2-fold (Figure 1C, 5 mM SP), a 15% 
reduction in the astrocytic protein did not reach statistical 
significance. Thus, SP decreased the astrocytic NAD(P)H 
/NAD+ ratio rather than cell number. As a result, both 
cancer and non-transformed cells greatly vary in their 
reactivity to SP tested in the NAD(P)H-dependent viability 
assays.
Non-linear regression analysis indicated that 
the viability decay kinetics is complex. In the cases of 
the well-expressed decay, the kinetic curves were best 
approximated by a biphasic process to a plateau value 
(Table 1, 96 h), which could become zero in case of high 
sensitivity to SP, exhibited by primary astrocytes (Table 
1, 5 h). For the SP-resistant cells, which did not show 
significant viability decreases in 96 h, the plateau value 
was set to zero for the approximation procedure, but the 
biphasic kinetics remained valid for these cells as well 
(Table 1, 96 h, zero values marked by asterisks). The first 
phase of the SP-induced viability decays corresponds 
to 10-20% of the total viability, which is lost rapidly, 
followed by at least an order of magnitude slower decay. 
Such a kinetics suggests that the primary decrease in 
cellular NAD(P)H, caused by the OGDH inhibition, is 
addressed by the activation of alternative pathways of 
NAD(P)H production. This activation slows down the 
viability decay kinetics, resulting in the decreased rates 
of the decays in the second phase of the concentration 
dependences (Table 1, 96 h). Remarkably, increasing 
the SP concentration changed the relative sensitivities of 
different cells to SP (Figure 2). At SP≤0.1 mM (Figures 
2A, 2B) U87 cells are even more reactive than HSF, while 
A549, MOGGCCM and T98G are resistant to SP action. 
However, at SP≥1 mM U87 cells become less susceptible 
than the A549, MOGGCCM and T98G cells, which, in 
contrast, acquire a high sensitivity to SP, comparable 
to that of HSF (Figure 2C, Figure 1). The change in the 
relative SP resistance with increasing SP concentration 
suggests varied abilities of different cells to adapt to the 
OGDH inhibition by SP.
The next series of experiments focused on the most 
malignant type of glioma (WHO grade IV), glioblastoma, 
as these cells are often presumed to have no metabolic 
flux through OGDH [11, 23-26]. In addition to several cell 
lines derived from glioblastoma multiforme, we also used 
primary cancer cells isolated from human glioblastoma. 
In the latter case, we employed only freshly isolated 
cells at a low number of passages, because after freezing 
and thawing the cells changed morphology and growth 
properties. To better understand the initial metabolic 
damage induced by SP, we tried to limit the possibility 
of cellular adaptation by reducing the SP exposure time 
to 24 h. The choice of this time point took into account 
that the glioblastoma cell lines incubated with SP for 96 
h, exhibited a distinct adaptive response, decreasing their 
SP reactivity with incubation time (Figures 1A, 1B; Table 
1, 96 h). On the other hand, after incubation with SP for 
5 h, the NAD(P)H levels of the glioblastoma cells did not 
change even in the minimal medium (Figure 1C). In view 
of some studies which showed that relative sensitivity 
Figure 1: Concentration dependence of cellular viability on the OGDH inhibitor SP. Legends on the graphs specify the 
cell lines and color code used. Values are means ± SEM from ≥ 3 independent experiments. Experimental curves were approximated 
by the biphasic exponential decay equations with parameters given in Table 1. A, B. Different cancer cell lines and primary human skin 
fibroblasts (HSF) were incubated for 96 h in the presence of different concentrations of SP in rich medium, and cellular NAD(P)H:MTT 
oxidoreductase activity was assayed as viability indicator. C. For a comparison of transformed (C6 rat glioma) and non-transformed (rat 
astrocytes) glial cells, short incubation times (5 h) in SP-supplemented HBSS medium were used.
Oncotarget26403www.impactjournals.com/oncotarget
of cells to treatments may depend on the viability test 
applied [41, 42], we also assessed the relative sensitivity 
of the glioblastoma cells to SP by different viability tests 
commercially available. As seen in Figure 3A, using 
the NAD(P)H-dependent CellTiterBlue viability test, 
we confirmed a lower resistance to SP of T98G cells, 
compared to U87 cells, as observed in the NAD(P)H- 
dependent MTT test (Figure 1B). The viability decrease 
in these different NAD(P)H-dependent tests exhibited the 
expected time dependence. That is, at 20 mM SP viability 
of T98G cells was reduced less in 24 h of the treatment 
(down to 80% of control, Figure 3A), compared to 96 h 
(down to 35% of control, Figure 1B). However, kinetic 
analysis of the viability decays at 96 and 24 h showed that 
decreases in the decay constants for the rapid and slow 
phases (kfast and kslow, Table 1) were associated with the 
changes in the amplitudes of the rapid and slow phases 
(Vfast and Vslow, Table 1). Thus, reduction of the time of SP 
exposure did not allow one to resolve the fast and slow 
phases. Their interdependence supports the assumption 
that the phases are due to the fast initial decrease in 
NAD(P)H by SP, which is slowed down by cellular 
adaptations at increasing SP exposures.
In Figure 3B, viability was assessed by determining 
cellular ATP levels, using the highly sensitive luminescent 
CellTiterGlo assay. This ATP-based assay was earlier 
shown to be a more sensitive indicator of the SP reactivity 
of primary neurons, compared to the NAD(P)H-dependent 
assay [42]. However, as seen from Figure 3B, also according 
to the CellTiterGlo assay, primary cerebellar granule neurons 
from rat do not significantly differ from the glioblastoma 
cells in their SP reactivity. As a result, the data presented 
in Figures 1-3 indicated that oncotransformation in different 
types of cancer including glioblastoma, does not necessarily 
exclude the high regulatory significance of the OGDH-
catalyzed reaction, inherent in normal metabolism [19-22].
Table 1: Parameters of the non-linear regression analysis of the viability (V) decay upon incubation of cells with SP 
Time, assay Cell line
Parameters of the viability decay regression
V0 Vfast Vslow kfast, mM-1 kslow, mM-1 Plateau
96 h, MTT
SK-NA-S 98 8 33 14 0.12 53
A549 100 9 64 8 0.12 27
C6 101 11 89 112 0.03 0*
N2A 94 - 19 - 0.1 75*
U87 100 19 82 ~2*105 0.01 0*
HSF 96 21 36 9 0.24 39
T98G 98 23 51 3 0.14 24
MOGGCCM 99 26 53 1.6 0.13 20
5 h, MTT
Primary rat 
astrocytes 100 20 80 90 0.09 0
24 h, CTB
LN405 103 - 103 - 0.004 0*
1321N1 105 - 105 - 0.001 0*
U87 105 7 - 0.8 - 98*
T98G 105 - 76 - 0.02 28*
52/11 102 24 78 1.1 0.02 0*
85/13 102 - 56 - 0.01 46*
Experimental curves in Figures 1 and 3 with significant viability decays were best approximated by the biphasic exponential 
equation: V
SP
=Vfast*e
-k
fast
*[SP] + Vslow*e
-k
slow
*[SP] + Plateau, where Vfast=(V0-Plateau)*PercentFast*0.01; Vslow=(V0-Plateau)*(100-
PercentFast)*0.01. Plateau is V at infinite times; PercentFast is the fast fraction of the span from V0 to Plateau. For the SP-
resistant cell lines exhibiting low amplitude of decay under experimental conditions, plateau could not be defined. In these 
cases (marked as *) the decay equations were simplified by manual setting the plateau value to zero. Then, if the regression 
constant kslow approached zero, the corresponding Vslow was considered as plateau. The residual fraction (Vfast) was considered 
as the fast or slow step according to the value of the regression constant kfast. The highly variable kfast and differences between 
the regression parameter V0 and 100%, comparable to Vfast, result from insufficient resolution of the fast process by regression 
analysis due to experimental limitations.
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Figure 3: Dependence of viabilities of different glioblastoma cells on the OGDH inhibitor SP. Cells were incubated for 24 h 
in the SP-supplemented rich medium. Experimental points are presented as means ± SEM. Four independent experiments with each cell 
line (1321N1, U87, LN405, T98G) were performed. As the primary human glioblastoma cells changed morphology after freezing-thawing, 
only the results obtained with the non-frozen cells are shown. A. CellTiterBlue assay of cellular NAD(P)H:resazurin oxidoreductase 
activity. In the color code-specifying legend the cell lines are presented in the order of decreasing cellular sensitivity to SP. Dashed lines 
show the results of single experiments with the freshly isolated primary glioblastoma cells (85/13 and 52/11). Experimental curves were 
approximated by the biphasic exponential decay equation with parameters given in Table 1. B. CellTiterGlo test of cellular ATP levels. 
Cellular sensitivity to SP is marked in shades of grey.
Figure 2: Change in relative sensitivity of different cell lines to SP with increasing SP concentrations. Data of Figure 
1A and 1B were used to range the cell lines according to the strength of their response to the SP exposure (96 h). The strength is colored 
in shades of grey. Statistical significance of the decreases in viability against the corresponding controls (*, p≤0.05) was determined by 
two-way analysis of variance (ANOVA) followed by Tukey test for multiple comparisons. A. SP 0.01 mM. B. SP 0.1 mM. C. SP 10 mM.
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Non-equal sensitivity of the glioblastoma 
NAD(P)H and ATP levels to SP delineates 
different metabolic types of glioblastoma
As shown above, the different viability tests based 
on assessing the NAD(P)H levels (MTT and CellTiterBlue) 
gave coinciding results. However, the responses of the 
glioblastoma ATP and NAD(P)H levels to SP treatment 
were not necessarily equal. For instance, the amplitude of 
the viability impairment of the primary glioblastoma cells 
(52/11) was lower when ATP levels were assayed. On the 
other hand, in U87 cells, a statistically significant 15% 
decrease in ATP levels was detected (Figure 3B), although 
NAD(P)H levels remained unperturbed under the same 
conditions (Figure 3A). Comparison of sensitivity to SP 
of cellular ATP and NAD(P)H in Figure 4 demonstrates 
that some glioblastoma cells exhibited a higher sensitivity 
in the ATP assay (U87, 1321N1, 85/13) and others in the 
NAD(P)H-based assay (T98G, 52/11). Assuming the ATP/
NAD(P)H ratio as a cellular indicator of the oxidative 
phosphorylation efficiency, one could use the SP treatment 
to delineate the two metabolic sub-types of glioblastoma. 
These sub-types show a different interaction between 
TCA cycle impairment and oxidative phosphorylation. 
The glioblastoma cells increasing the ATP/NAD(P)H 
ratio under SP exposure (Figure 4, T98G and 52/11 
cells) respond to the TCA cycle impairment by a higher 
transformation of the oxidation-derived energy (NAD(P)H) 
into the biosynthetic energy (ATP). In contrast, the 
glioblastoma cells decreasing the ATP/NAD(P)H ratio 
upon SP exposure (Figure 4, U87, 1321N1 and 85/13 
cells) accumulate NAD(P)H rather than convert it to ATP, 
when the TCA cycle is impaired.
A study of the time-dependence of the SP-induced 
changes in cellular ATP levels demonstrated intermediary 
increases in cellular ATP during the exposure to SP 
(Figure 5), which has previously also been observed in 
primary neurons [42]. As seen in Figure 5A, increasing 
the incubation time from 5 to 24 h in the presence of 0.5 
mM SP revealed ATP increases in T98G and U87 cells. 
However, at 20 mM SP, U87 and T98G cells could only 
preserve their ATP levels between 5 and 24 h, whereas a 
similar increase in ATP could be observed in LN405 cells 
which were more resistant to SP (Figure 5B). Remarkably, 
1321N1 and 52/11 cells, which strongly differ in their 
sensitivity to SP according to the NAD(P)H-dependent 
assay (Figure 3A), were both unable to stabilize their ATP 
levels, as revealed upon incubation of 1321N1 and 52/11 
Figure 4: Comparison of the SP-induced changes in viabilities of glioblastoma cells, as determined by assays dependent 
on ATP (CellTiterGlo) or NAD(P)H (CellTtiterBlue). Cultured cells were incubated in rich medium supplemented with 20 mM SP 
for 24 h. The cells are ordered according to their ability to preserve the NAD(P)H levels. The data are presented as means ± SEM. Number 
of experiments as in Figure 3. Statistical significance of the differences between the two assays (#, p≤0.05) was determined by two-way 
ANOVA followed by Tukey test for multiple comparisons. The same statistical analysis of the SP-affected vs control cells revealed that 
levels of ATP in all cells but LN405 were different from those in the corresponding controls.
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cells with 20 mM SP (Figure 5B). This finding indicates 
that the high cellular NAD(P)H levels are not necessarily 
indicative of unperturbed metabolism.
The observed differences in the SP sensitivity 
of the glioblastoma NAD(P)H and ATP levels did not 
correlate with the glioblastoma cell growth rates. At the 
beginning of the SP exposure, the cells were usually at 
about 60% confluence. The determination of ATP levels 
in control cells, i.e. those incubated for 24 h without SP 
and providing for reference values in Figure 5, allowed 
us to estimate growth of the different cultures used in the 
experiment, between 5 and 24 hours. The corresponding 
increases in ATP levels were between 0% (85/13) and 
60% (1321/N1). These proliferation indices did not reflect 
the SP sensitivity of the NAD(P)H levels of the cells. In 
particular, the SP sensitivity of NAD(P)H levels in both 
85/13 and 1321/N1 cells was similarly low (Figure 3A, 
Figure 4). On the other hand, the SP-sensitive T98G cells 
and the SP-resistant LN405 cells (Figure 3A), which also 
significantly differed in the ability to preserve their ATP 
levels (Figure 5), showed a similar 30% growth under 
control conditions during the experiment. As a result, the 
time- and concentration-dependent changes in cellular ATP 
levels and ATP/NAD(P)H ratios due to SP treatment do 
not correlate with the cell growth rate, but depend on cell-
specific molecular mechanisms employed to compensate 
for perturbation in the OGDH reaction.
Correlation of the cancer cell sensitivity to SP 
with transcriptomics data
Cell-specific significance of the OGDH reaction 
for the viability parameters may be assessed by cellular 
expression of the enzymatic components of the OGDH 
multi-enzyme complex and enzymes of the OGDH-linked 
network (Figure 6), which are indicators of the functional 
activity of different OGDH-dependent pathways. Our 
analysis of expression of particular enzymes of interest 
used the global transcriptomic data deposited in the Gene 
Expression Omnibus (GEO) database (see Methods). The 
Figure 5: Time dependence of cellular ATP levels at low and high concentrations of SP. A. SP 0.5 mM. B. SP 20 mM. At both 
SP concentrations, the cell order corresponds to the cellular ability to preserve ATP levels after 24 h at 0.5 mM SP. Values are means ± SEM 
from 4 independent experiments with cell lines. For primary glioblastoma cells 85/13 and 52/11 one independent experiment was done with 
freshly isolated cells, as cell morphology changed after freezing-thawing. Statistical significance (#, p<0.05) between the differences in ATP 
at 5 and 24 h is shown, as determined by two-way ANOVA followed by Tukey test. Compared to the corresponding controls, 20 mM SP 
induced statistically significant decreases in ATP levels in all cases except for 1321N1 and 52/11 at 5h, and LN405 at 24 h.
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combined expression of the two functionally competent 
isoforms of 2-oxoglutarate dehydrogenase (further 
denoted as OGDH(L)), coded by the OGDH (house-
keeping isoform) and OGDHL (brain isoform) genes 
[43, 44], was considered for estimation of the OGDH 
function. In the following section, we will mainly refer 
to the relative transcript abundances given in Table 2 
by the enzyme/gene names only. Relative abundance 
of the functional 2-oxoglutarate dehydrogenase multi-
enzyme complex in the cell lines was estimated as the 
ratio of transcripts of genes coding for the rate-limiting 
component OGDH(L) (OGDH and OGDHL genes) and 
the second substrate-specific component dihydrolipoyl 
succinyltransferase (DLST gene). The four cell lines for 
which the results of several different experiments on 
gene expression were found in GEO (A549, T98G, SK-
NA-S, U87), were compared, taking into account the 
higher sensitivity to SP of A549 and T98G vs SK-NA-S 
and U87 (Figure 1A and 1B). The relative sensitivities in 
the NAD(P)H-based assay (Figure 1) were chosen for the 
comparison, assuming the NAD(P)H levels to be more 
direct indicators of the inhibition of the NADH-producing 
OGDH than the ATP levels. The colored pattern of Table 
2 exposes not only the similarity in the abundance of the 
OGDH(L)-related gene transcripts in the SP-sensitive 
lines A549 and T98G, but also the difference between 
these SP-sensitive lines and those rather resistant to SP, 
i.e. SK-NA-S and U87. First of all, abundances of the 
OGDH(L)-DLST sub-complex were often shifted to 
lower values in A549 cells (from 0.05 to 0.7) and T98G 
cells (abundance coefficients from 0.3 to 1.3), compared 
to SK-NA-S cells in culture (coinciding values 1.1) and 
U87 (abundance coefficients from 0.8 to 3). The lower 
abundances of the OGDH(L)-DLST sub-complex in 
A549 and T98G correlate with a higher susceptibility of 
NAD(P)H levels in these cell lines to SP (Figures 1-3). 
As shown earlier, cellular viability depends on the spare 
OGDH threshold capacity [45]. Obviously, the threshold 
is easier reached by the OGDH(L) inhibition in cells with 
lower levels of the functional OGDH(L) multi-enzyme 
complex, explaining the observed correlation between 
the OGDH(L) expression and the SP sensitivity. The cell-
specific impact of the OGDH(L) function may also be 
seen from the relative expression of OGDH(L) compared 
to other enzymes of the TCA cycle. In fact, in the cell 
lines A549 and T98G which are more sensitive to SP, 
the lower abundance of the functional OGDH(L)-DLST 
sub-complex (Table 2, yellow pattern) coincides with 
Figure 6: Network of the OGDH(L)-related reactions, shunting the TCA cycle block by the OGDH(L) inhibitor SP. 
The relevant part of the TCA cycle is shown in blue, the major transamination reaction by aspartate aminotransferase (GOT) is shown in 
red. Other pathways linked to OGDH(L) and affiliated with the TCA cycle are in black. They include transamination of 2-oxoglutarate 
(2-OG) with branched chain 2-amino acids (BCAA) to branched chain 2-oxo acids (BCOA), with gamma-aminobutyric acid (GABA) to 
succinyl semialdehyde (SSA) and with tyrosine. The transamination products are further oxidized to the branched chain acyl-CoA (BC-
acyl-CoA), succinyl-CoA, acetyl-CoA, succinate and fumarate, as shown in the scheme. Glutamate accumulated due to the transmination 
of 2-oxoglutarate, may be oxidized to 2-oxoglutarate or exchanged for extracellular cystine. The enzymes and cystine/glutamate antiporter 
are given by human gene names, as in Table 2, and framed. Dotted lines denote multiple reactions in the pathways. See text for other details.
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Table 2: Assessment of the relative expression of OGDH(L) and its network proteins in the cell lines differing in their 
resistance to SP (SK-N-AS and U87 are more resistant than A549 and T98G, Figure 1) 
Enzymes and
pathways
Ratio of 
transcripts 
SK-N-AS
xenografts
SK-N-AS A549 T98G U87
n=2 n=4 n=3 n=1 n=1 n=3 n=1 n=3 n=2
OGDHC
OGDH(L)/
DLST
0.5 1.1 1.1 0.7 0.3 0.05 0.3 1.3 0.8 3
            
TCA cycle
OGDH(L)/
OGDH(L) 1 1 1 1 1 1 1 1 1 1
 SUCLG1.2/OGDH(L) 3.9 1.9 8 15 8 78 16 22 9 0.7
 SDH(A+B)/OGDH(L) 2.3 1.9 7 10 4 39 10 7 6 3
 FH/OGDH(L) 3.7 1.1 8 9 4 70 13 15 4 0.5
 MDH2/OGDH(L) 9.0 1.3 21 27 9 127 7 16 10 3
CS/OGDH(L) 5.6 1 9 11 5 44 22 12 5 0.05
IDH2/OGDH(L) 2.7 0.8 0.6 4 1.4 6 4 2 0.6 0.3
           
Transaminases
using OG
GOT(1+2)/
OGDH(L) 4 2 6 12 6 38 16 9 6 1
BCAT(1+2)/
OGDH(L) 1 1 2 5 2 10 2 14 0.8 0.3
ABAT/
OGDH(L) 0.1 0.3 0.3 2 0.1 0.4 0.4 0.1 0.1 0.004
TAT/OGDH(L) 0.1 0.3 0.05 0.2 0.02 0.1 0.1 1 0.4 0.01
           
BCKADH
BCKD A+B/
OGDH(L) 1 1 1 2 1 5 1 1 1 0.5
DBT/OGDH(L) 0.3 1 3 4 3 1 13 10 1 0.01
DLDH/
OGDH(L) 3 1 13 12 4 62 11 10 6 0.6
           
Glu 
metabolism
GLUD(1+2)/
OGDH(L) 1 2 2 4 4 37 7 5 4 1
GLUL/
OGDH(L) 1 1 6 1 0.1 2 11 6 2 0.1
GLS/OGDH(L) 2 1 4 4 2 23 4 7 2 0.1
GLS2/OGDH(L) 0.01 0.2 0.04 0.01 0.01 0.2 0.2 0.3 0.04 0.004
SLC7A11/
OGDH(L) 0.1 1 1 11 6 72 9 15 1 0.005
           
(Continued )
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Enzymes and
pathways
Ratio of 
transcripts 
SK-N-AS
xenografts
SK-N-AS A549 T98G U87
n=2 n=4 n=3 n=1 n=1 n=3 n=1 n=3 n=2
GABA shunt
GAD(1+2)/
OGDH(L) 0.1 0.5 0.1 0.1 0.1 0.2 0.4 0.4 0.6 0.2
SSADH/
OGDH(L) 0.3 1 1 1 1 6 0.2 1.0 0.01 0.004
           
Tyr 
degredation FAH/OGDH(L) 0.2 1 2 2 1 6 4 0.4 3 1
AACS/
OGDH(L) 1 1 2 2 1 7 1 4 1 0.2
           
Glu receptors
(ionotropic)
GRIA/OGDH(L) 0.4 1 0.1 0.1 0.3 0.2 0.6 0.1 0.1 0.05
GRIN/OGDH(L) 0.3 2 1 1 0.3 1 1 2 1 3
The GEO database was used to extract the transcript values as described in Methods. Enzymes and cystine/glutamate antiporter 
SLC7A11 are given by the abbreviations used for human gene names. The corresponding reactions are shown in Figure 6, 
except for glutaminase (isoforms GLS, GLS2) and glutamine synthase (GLUL), which are omitted for simplicity. Signals 
of the gene transcripts from n datasets employed to obtain the data presented in the corresponding columns were averaged 
dependent on coincidence, as described in methods. Blue pattern shows relative abundance of the TCA cycle enzymes in 
each cell line (vertical comparison), with bright blue marking the transcript ratios in excess to the minimal one shown in 
pale blue. Yellow pattern refers to the comparison of SK-N-AS, A549, U87 and T98G (horizontal comparison), regarding 
the functional OGDH(L) subcomplex (OGDH(L)/DLST) and its network proteins. Intense yellow marks the range of higher 
expression ratios compared to the range of expression ratios in pale yellow. Some differences could be associated with the 
SP resistance only for T98G and U87 cells. For comparison between cells in culture and in vivo, the available experiment on 
SK-N-AS xenografts, obtained by inoculating SK-N-AS cells into nude mice (experiment under the GEO accession number 
GSM302678), is included.
the lowest abundance of OGDH(L) compared to other 
TCA cycle enzymes (Table 2, blue pattern). In contrast, 
the cells more resistant to SP (SK-N-AS and U87), were 
not characterized by the minimal transcript abundance 
of OGDH(L) among the TCA cycle enzymes. In these 
SP-resistant cells, the TCA cycle “bottle-neck” is shifted 
upstream of OGDH(L), to isocitrate dehydrogenase or, 
according to some experiments with U87 cells, to citrate 
synthase (Table 2, blue pattern). Remarkably, according 
to the TCA cycle expression analysis, relative OGDH(L) 
abundance in SK-N-AS cells differs in the cell culture and 
tumors grown in vivo (SK-N-AS xenografts) (Table 2). 
The difference suggests a condition-dependent shift of the 
TCA cycle “bottle-neck” to OGDH(L) in xenografts, i.e. 
in vivo.
Thus, according to the expression analysis, 
OGDH(L) may limit the TCA cycle flux in A549 and T98G 
cells, which increases their sensitivity to the OGDH(L) 
inhibition. In contrast, no limitation of the TCA cycle flux 
in the SK-N-AS and U87 cells corresponds to the lower 
dependence of these cells on the OGDH(L) inhibition 
by SP (Figure 1). As a result, the relative abundance of 
functional OGDH(L) correlates with cellular sensitivity to 
OGDH(L) inhibition.
Along with the different impact on cell viability of 
the OGDH reaction itself, the viability impairment due 
to perturbation in the OGDH(L)-catalyzed reaction will 
depend on cellular ability to shunt the inhibited reaction 
and/or activate alternative pathways of NAD(P)H or 
ATP production. The cell-specific networks (Figure 6) 
respond to the OGDH inhibition according to the mass 
law action. That is, accumulation of 2-oxoglutarate due 
to the OGDH(L) inhibition increases saturation of the 
enzymes and transporters of this network in accordance 
with their expression and substrate affinity, stimulating the 
transformations of 2-oxoglutarate beyond that inhibited 
by SP. It was previously shown in a variety of cells and 
tissues that the inhibition of OGDH(L) by SP increases 
the transamination of 2-oxoglutarate to glutamate 
and other amino acids. As a result, the degradation of 
amino acids, particularly those restoring the TCA cycle 
downstream of OGDH(L), is stimulated [42, 46, 47]. 
The closest to OGDH(L) restoration of the TCA cycle 
occurs through the dehydrogenase of the branched chain 
2-oxo acids and GABA shunt, producing along with 
NADH also the downstream intermediates succinyl-
CoA and succinate (Figure 6). Oxidative deamination 
of glutamate by glutamate dehydrogenase with the 
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concomitant production of NADH, 2-oxoglutarate and 
NH4
+ may restore 2-oxoglutarate, further increasing its 
transamination with the amino acids (Figure 6). Regarding 
potentially toxic NH4
+ produced in this reaction, and the 
importance of glutaminase in cancer transformation [11], 
cellular abundances of glutamine synthase (GLUL) and 
glutaminase (isoforms GLS and GLS2) were also taken 
into consideration (Table 2), although for the sake of 
simplicity these reactions are not shown in Figure 6. 
The data presented in Table 2 indicates that many of 
the enzymes involved in these 2-oxoglutarate-linked 
reactions, are more abundant in the SP-sensitive (A549 
and T98G) than in the SP-resistant (SK-N-SA and U87) 
cells. That is, metabolic networks with minimal OGDH(L) 
abundance potentially limiting the TCA cycle flux at the 
2-oxoglutarate degradation step (Table 2, abundances 
in blue), are characterized by a higher expression of the 
pathways utilizing 2-oxoglutarate in other reactions (Table 
2, abundances in yellow). When OGDH(L) is inhibited in 
such metabolic networks, these pathways may compensate 
for the inhibition by generating the products (NADH and 
succinyl-CoA) or the downstream intermediate (succinate) 
of the OGDH(L) overall reaction. However, the high 
expression of these compensatory pathways in A549 and 
T98G cells compared to SK-N-AS and U87 ones (Table 2), 
does not support cellular ability to preserve the NAD(P)H 
levels in the former compared to the latter, when cells are 
exposed to SP (Figure 1A and 1B).
Apart from dysfunctional metabolism of 
dicarboxylates, tyrosine degradation, initiated by the 
tyrosine transamination with 2-oxoglutarate [48-50], 
and glutamate exchange for cystine through xc
- cystine/
glutamate antiporter SLC7A11 [51-54], are considered 
important for cancer cell metabolism. Stimulation 
of tyrosine degradation to fumarate and acetoacetate 
(terminal step catalyzed by FAH, Figure 6), with ATP-
dependent acetoacetate activation to acetoacetyl-CoA 
by AACS (not shown in Figure 6), may occur due to 
SP-induced increase in tyrosine transamination with 
accumulated 2-oxoglutarate, catalyzed by TAT (Figure 
6). However, abundances of the enzymes of the tyrosine 
degradation pathway (Table 2), where TAT is supposed to 
be rate-limiting, do not exhibit a clear correlation of this 
pathway with cellular resistance to SP. In contrast, along 
with other enzymes of glutamate metabolism, the cystine/
glutamate antiporter SLC7A11 is additionally more 
abundant in cells with NAD(P)H levels less resistant to 
SP (A549 and T98G, Table 2).
Given that SP increases glutamate production 
from accumulated 2-oxoglutarate (Figures 8, 9), while 
glioblastoma cells may be impaired by glutamate 
excitotoxicity through ionotropic receptors [52], we 
also compared expression of these receptors as potential 
contributors to cellular sensitivity to SP. Indeed, Table 2 
shows that the range of expression of the AMPA glutamate 
receptors (all isoforms of GRIA) was somewhat higher in 
the more sensitive T98G cells (abundances from 0.1 to 
0.6), compared to resistant U87 cells (abundances from 
0.05 to 0.1).
SP-induced changes in metabolic profiles of 
glioblastoma cells with different SP resistance in 
NAD(P)H-based viability tests
To understand molecular mechanisms of cellular 
responses to SP of glioblastoma cells, we also characterized 
cellular heterogeneity using metabolic profiling of 
glioblastoma cell lines with different SP resistance, i.e. 
U87 and T98G lines. Remarkably, metabolic profiles of 
these cells under control conditions were different. It is 
obvious from Figure 7A that, compared to U87, T98G cells 
have lower levels of most amino acids, with statistically 
significant decreases in glycine, threonine, tyrosine, 
phenylalanine, methionine and cystathionine. However, 
alanine was increased concomitant with decreased lactate, 
in T98G vs U87 cells. Metabolic difference between T98G 
and U87 cells is further supported by different levels of 
pantothenic and benzoic acid, isomaltose, xylose and 
glycerol-3-phosphate (Figure 7A).
Given the large differences in the metabolic profiles 
of T98G and U87 cell lines under control conditions, 
the metabolic changes observed in response to the SP 
treatment are expected to be cell-specific too, which was 
indeed observed (Figure 7B). In order to detect the primary 
metabolic changes induced by SP, we used the treatment 
conditions which did not significantly change the viability 
indicators, i.e. cells were incubated with 0.5 mM SP for 
24 h. Already under this low SP concentration, metabolic 
perturbations were detectable in both the SP-sensitive T98G 
and SP-resistant U87 cells (Figure 7B). The signature of 
the SP inhibition of OGDH, an increase in 2-oxoglutarate 
[47], was well expressed in the two cell lines. In accordance 
with the SP effect on NAD(P)H levels (Figure 1, Figure 
3A), the more sensitive T98G cell line exhibited many more 
changes after the treatment with SP, while in U87 cells only 
alanine and β-alanine increased significantly along with 
2-oxoglutarate (Figure 7B). It must be noted, however, that 
even the limited changes in the U87 metabolic profile were 
indicative of serious failures, such as perturbed function 
of the TCA cycle (alanine, 2-oxoglutarate) and increased 
degradation of pyrimidine nucleotides (β-alanine). The 
different patterns of the SP-induced changes in the amino 
acid pool of the T98G and U87 cells reciprocated initial 
differences in the pool of the cells under control conditions. 
That is, the originally lower levels of many amino acids in 
T98G cells increased and became higher than in U87 cells. 
An important difference between the T98G and U87 cells 
was observed with regard to SP-induced changes in the TCA 
cycle intermediates beyond 2-oxoglutarate. Succinate and 
fumarate accumulated in T98G cells treated with SP much 
more than in U87 cells (Figure 7B). SP also significantly 
changed sugars, such as isomaltose, xylose, altrose and 
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galactose in T98G cells compared to U87 cells. Furthermore, 
increased adenosine-5-monophosphate (AMP) was observed 
in T98G vs U87 cells after SP treatment. Thus, the original 
metabolic profiles of T98G and U87 cells (Figure 7A) and 
their responses to SP (Figure 7B) supported the cell-specific 
metabolism and different compensatory pathways suggested 
by the transcriptomics data (Table 2).
Glutamine and glutamate as metabolic 
indicators of SP action in glial and neuronal cells
Because of efficient transamination between 
2-oxoglutarate and glutamate, both compounds were 
indicators of the OGDH inhibition by SP in different 
systems [42, 47]. However, metabolic profiling of the 
Figure 7: Heat map visualization of the relative metabolite levels in T98G and U87 cells. Metabolites were determined as 
described in Methods.The color code of the heat maps is given at the log(2) scale above the diagrams. Extracts were obtained in at least five 
independent experiments. Statistical significance was determined by Student’s t test (P < 0.05). Asterisks (*) indicate significant difference 
from the control shown as the blank map. Circles (º) indicate significant difference between the SP-treated T98G cells and U87 cells. 
A. Control cells. Metabolite levels in T98G cells were normalized to those of U87 cells. B. Cells treated with 0.5 mM SP for 24 h in rich 
medium. Metabolite levels after the SP treatments of T98G or U87 cells were normalized to the respective controls. 
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SP-treated glioblastoma cells showed a much higher 
accumulation of glutamine, not glutamate (Figure 7). This 
was in good accordance with the known high activity of 
glutamine synthase (GLUL, Table 2) and the glutamate/
cystine antiporter (Table 2), competing for the intracellular 
glutamate in glioblastoma cells [54]. In contrast, under 
similar conditions, SP-treated neurons were characterized 
by primary accumulation of glutamate, with the glutamine 
increase following, but never exceeding that of glutamate 
(Figure 8). The difference was the most obvious at low 
(0.2 mM SP for 2 h, Figure 8A) and high (2 mM SP for 
5 h, Figure 8B) exposures of neurons to SP, confirming 
recent data on the presence of glutamine synthase not only 
in astrocytes, where the major part of the brain enzyme 
is localized, but also in neurons [55]. It was therefore 
of interest to determine if glutamate would increase in 
SP-exposed neuroblastoma cell lines. As seen in Figure 
9, an up to 2-fold increase in glutamate was observed 
in neuroblastoma in the SP concentration-dependent 
manner. Moreover, in both neurons (Figure 8B) and 
neuroblastoma (Figure 9), the SP-induced changes in the 
level of glutamate exhibited a complex time dependence, 
with an initial increase in intracellular glutamate content 
followed by a decrease. The decreases in glutamate were 
not attributable to cell loss, because the levels of glutamate 
were normalized per protein content. It is worth to note 
however, that neuronal, but not neuroblastomal, protein 
was significantly reduced by SP (Figure 8C vs Figure 
9). The perturbed neuronal metabolism associated with 
significant (down to 50%, Figure 8C) loss of cellular 
protein was probably responsible for a metabolic switch, 
leading to the secondary increase in intracellular glutamate 
at extensive SP exposure (for 5 h at 0.5 to 2 mM SP, 
Figure 8B).
Increases in glutamate and reactive oxygen 
species (ROS) upon incubation of neuroblastoma 
N2A cells with SP
Some studies demonstrated that in neuroblastoma 
cells glutamate caused oxidative stress and mitochondria-
mediated apoptosis [56, 57], reminiscent of the glutamate-
induced excitotoxicity in neurons. Such neurotoxic action 
of glutamate in neuroblastoma was observed despite 
the significant decrease in expression of the NMDA 
receptors in brain cancer cell lines [58]. We therefore 
checked if glutamate accumulation in neuroblastoma 
exposed to SP was associated with changed ROS levels. 
As seen from Figure 9, a significant increase in glutamate 
upon incubation of N2A cells with SP was paralleled 
by an increase in superoxide anion radical production 
(reactive oxygen species, ROS), as detected by lucigenin 
chemiluminescence, already at a concentration of 0.1 
mM SP. However, a further increase in SP concentration 
(from 0.1 to 2.5 mM) decreased ROS, although the 
glutamate increased up to 2-fold before decreasing at 
high SP (5 mM) (Figure 8, green line). Crucially, all the 
changes occurred before any significant decay in cellular 
viability or cell loss could be detected by the MTT test 
or protein assay (Figure 9). The statistically significant 
decrease in viability, corresponding to a 15% decrease 
in the NAD(P)H-dependent MTT-reductase activity, was 
observed only following 5 h incubation with 10 mM 
SP. Under these conditions, ROS showed up to a 2-fold 
Figure 8: Time-dependent changes in the intracellular content of glutamate, glutamine and protein upon incubation 
of rat cerebellar granule neurons in the SP-supplemented growth medium. The data were obtained using five independent 
neuronal cultures. Statistical significance was estimated using two-way analysis of variance (ANOVA) followed by Dunnett’s test for 
multiple comparisons. Difference to the control values (p≤0.05) is indicated by asterisks. A, B. Glutamate and glutamine. C. Cellular 
protein.
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decrease from control values (not shown), suggesting that 
cellular NAD(P)H may be consumed by ROS-scavenging 
reactions. Thus, our study pointed to a biphasic kinetic of 
the SP-induced changes in the glutamate and ROS levels 
in neuroblastoma, with a decrease in accumulated ROS 
followed by a decrease in cellular reducing power.
DISCUSSION
Oxidative decarboxylation of 2-oxoglutarate 
is significant for tumor cell metabolism and 
survival
Cancer cells are widely known to increase their 
glycolysis under normoxic conditions, which led 
Otto Warburg to hypothesize that mitochondria and 
oxidative phosphorylation are impaired in cancer. 
Although this hypothesis was not supported by the 
following studies which showed that in the majority 
of cancer cells mitochondria are functional and the 
capacity for oxidative phosphorylation normal [12, 
38], the flux through the mitochondrial TCA cycle 
in cancer remains under debate, as the cycle is often 
supposed to be truncated at the isocitrate dehydrogenase 
step upstream of OGDH. Using selective inhibition of 
OGDH(L) by SP allowed us to reveal the metabolic 
significance of the OGDH(L)-catalyzed reaction in 
a variety of cancer cells. This finding has specific 
importance in view of the controversial suggestions 
of the glutaminolysis-coupled pathways, discussed in 
the literature. Although glutaminolysis in normal cells 
is known to require OGDH, cancer cells frequently 
have mutations in the TCA cycle enzymes succinate 
dehydrogenase and fumarate hydratase [59] downstream 
of OGDH, and also reduce the OGDH substrate 
2-oxoglutarate to 2-hydroxyglutarate [26]. Owing to 
this, glutaminolysis in cancer cells was suggested to 
occur through the isocitrate dehydrogenase-dependent 
carboxylation of 2-oxoglutarate [25, 60, 61]. However, 
this interpretation of isotope tracer studies was not 
supported by independent studies [54, 62, 63] and 
is thermodynamically impossible because of a low 
intracellular concentration of gaseous CO2. Indeed, 
mammalian carboxylation needs ATP and biotin for the 
Figure 9: Changes in cellular NAD(P)H:MTT reductase activity, ROS, glutamate and protein after 5 h incubation of 
neuroblastoma N2A cells in SP-supplemented minimal medium. Means ± SEM from three independent experiments are shown. 
Statistical significance was estimated using one-way analysis of variance (ANOVA) followed by Dunnett’s test for multiple comparisons. 
Difference to the control values (p≤0.05) is indicated by asterisks.
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CO2 activation, and carboxylation of 2-oxoglutarate 
by the recombinant tumor mutants of isocitrate 
dehydrogenase has never been observed, even if the 
mutants do reduce 2-oxoglutarate to 2-hydroxyglutarate 
[26]. Analogous mutants of the isocitrate dehydrogenase 
homolog oxidizing homoisocitrate did not catalyze 
the carboxylation reaction either [64]. Our findings 
provide experimental evidence for the functional 
importance of the OGDH-dependent turnover of 
the TCA cycle in cancer cells, clearly showing that 
homeostasis of different types of tumor cells, including 
the most malignant glioblastoma cells, is significantly 
perturbed upon inhibition of oxidative decarboxylation 
of 2-oxoglutarate. However, the dramatic changes in 
cellular homeostasis due to SP treatment (Figures 7, 9) 
were poorly expressed in the viability tests, based on 
either ATP or NAD(P)H assays, at short exposure times 
(Figures 3, 9, [42]). Obviously, detection of differences 
in cellular proliferation by such assays implies a long 
incubation time, whereas metabolic indicators are best 
suited to detect homeostatic perturbations before they are 
translated into cell number.
We also show here that the cell-specific differences 
in sensitivity of the viability parameters to the OGDH(L) 
inhibition correlate with potential limitation of the TCA 
cycle flux by OGDH(L) (Table 2). The correlation 
between the gene transcript abundances (Table 2), 
sensitivity of cellular NAD(P)H to the OGDH(L) 
inhibition (Figures 1–3) and the SP-induced changes 
in metabolic profiles (Figure 7) supports the notion 
that the transcript abundances and protein expression 
are optimal for biologically relevant protein-protein 
interactions [65].
Both the OGDH(L) multi-enzyme complex and the 
TCA cycle metabolon are known as essential regulatory 
systems of cellular metabolism. The OGDH(L) complex 
has often been shown to limit the TCA cycle flux, 
especially under maximal metabolic load, whereas the 
2-oxoglutarate/glutamate ratio is key for the retrograde 
signaling from mitochondria to nucleus [19-22]. The 
physiological significance of the TCA cycle flux limitation 
by OGDH(L) is supported by the observed shift of the 
TCA cycle enzyme with minimal transcript abundance 
from isocitrate dehydrogenase to OGDH(L), when the 
independent database-deposited experiments on SK-
N-AS cells in culture are compared to the cells within 
tumors growing in mice (SK-N-AS xenografts) (Table 2). 
The shift in minimal transcript abundance may change 
the TCA cycle rate-limiting step, causing the known 
differences in the TCA cycle flux of cancer cells in vivo 
and in situ, particularly in utilization of glutamine [63]. 
As a result, tumor cells in vivo could be more sensitive 
to the OGDH(L) inhibition, compared to the same cells 
in culture. This is supported by the high sensitivity of 
the primary glioblastoma cells 52/11 to the OGDHC 
inhibition (Figure 3).
Comparison of SP action in normal and 
tumor cells
In this work, we have shown that both the normal 
and malignant cells may exhibit different reactivity to the 
OGDHC inhibition, with the reactivity also dependent 
on the assays employed. However, oncotransformation 
per se is not associated with insensitivity to the OGDH 
inhibition. Besides, the cell-specific metabolism results 
in cell-specific markers of SP reactivity. For instance, 
in neuronal cells SP causes a 2-fold (neuroblastoma, 
Figure 9) or a 3-fold (cerebellar granule neurons, Figure 
8) increases in glutamate, while in glioblastoma cells 
the changes in glutamate are not expressed, whereas 
glutamine increases about 2-fold (Figure 7). Moreover, 
similar changes in the same markers may be associated 
with different consequences for cellular homeostasis. 
That is, the similar SP-induced increases in glutamate of 
cultured primary neurons (Figure 8) and neuroblastoma 
cells (Figure 9) are observed together with a drastic 
difference at the protein level, which is strongly reduced 
by SP in neurons (Figure 8C), but not in neuroblastoma 
cells (Figure 9). A comparison with the published data 
also shows that, when SP acted on hippocampal neurons, 
their ROS production first decreased (at 0.2 mM SP), 
followed by an increase (at 0.5 mM SP) [66]. As shown in 
Figure 9, neuroblastoma N2A cells exhibited an opposite 
concentration dependence on SP: initial ROS increase 
at SP < 0.2 mM is followed by a decrease at SP > 0.2 
mM. Also in cervical cancer cells, down-regulation of 
the OGDH(L) gene was associated with a decrease in 
ROS [67], which we observe upon strong inhibition of 
OGDH(L) at SP > 0.2 mM in neuroblastoma (Figure 
9). Further confirming the biological significance of the 
interplay between the OGDH(L) function and cellular 
ROS production [66-70], these findings exhibit essential 
differences between neurons and neuroblastoma cells 
regarding the interplay, obviously dependent on the cell-
specific metabolic networks of compensatory reactions 
(Figure 6, Table 2). The network may also contribute to 
the cell-specific manifestations of the glutamate-induced 
excitotoxicity. In some experimental settings, the tumor 
cells used glutamate to increase their proliferation [53, 
58, 71]. Other studies revealed glutamate to induce 
oxidative stress and mitochondria-mediated apoptosis in 
neuroblastoma cells [56, 57], although these processes 
were not dependent on NMDA receptors mediating the 
glutamate excitotoxicity in neurons. In glioblastoma, 
glutamate could induce necrosis through ionotropic 
glutamate receptors and impairment of the cystine/
glutamate antiporter [52]. Our data on increased expression 
of GRIA receptors and the cystine/glutamate antiporter in 
T98G vs U87 glioblastoma cells (Table 2) agrees with a 
stronger sensitivity of the reducing power of T98G to SP 
(Figures 1–3). Thus, multiple mechanisms of glutamate 
action inside and outside cells, cell-specific protein 
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expression and variations in experimental settings may all 
contribute to the glutamate-induced outcome for cellular 
viability, followed by the dose-response curves in situ. 
Therefore, only understanding of molecular mechanisms 
involved in toxic drug effects helps translating the results 
of cellular research to in vivo conditions.
Specific inhibition of key enzymes as a tool 
to decipher molecular mechanisms of cancer 
cell heterogeneity: significance for therapeutic 
strategies
Transcriptomics (Table 2) and metabolic profiling 
under control conditions (Figure 7A) and when responding 
to drugs (Figure 7B) provide complementary data to 
decipher molecular mechanisms of heterogeneity of cancer 
cells. The differences between metabolic profiles of T98G 
and U87 cells (Figure 7A) are in good accordance with 
the transcriptomics data (Table 2), additionally supported 
by a 5-fold lower activity of the OGDH complex in 
T98G compared to U87 cells [72]. First, correlated 
differences in the TCA cycle intermediates, i.e. higher 
levels of 2-oxoglutarate and succinate, accompanied by 
lower levels of malate, pyruvate and citrate in T98G vs 
U87 (Figure 7A), agree with OGDH limiting the TCA 
cycle flux in T98G, but not in U87 cells. Second, a lower 
content of many amino acids in T98G vs U87 cells (Figure 
7A) may be due to increased steady-state transamination 
and oxidation of amino acids in T98G (Table 2). Third, 
a higher expression of the pathways metabolizing amino 
acids and generating succinate in T98G cells (Table 2) 
is confirmed by a significantly higher elevation of the 
amino acid pool and accumulation of succinate, observed 
in the SP-treated T98G compared to U87 cells (Figure 
7B). Remarkably, neither the restoration of the TCA 
cycle, nor the NADH generation in the compensatory 
reactions (i.e. glutamate dehydrogenase, succinate 
semialdehyde dehydrogenase and branched chain 2-oxo 
acid dehydrogenase, Figure 6) occurring in T98G cells 
exposed to SP, are able to support the control level of 
cellular reducing power to the same extent as in SP-treated 
U87 cells, where these pathways are less expressed. This 
non-trivial finding indicates that the metabolic impact 
of the same intermediates (such as NADH, succinyl-
CoA and succinate) arising through different pathways, 
is not equivalent. Other studies on glioblastoma cell 
lines arrived at similar conclusion regarding cellular 
metabolism of NAD(P)H [72] or glutamine [54]. Indeed, 
perturbed fluxes often result in metabolic disbalance 
causing increased ROS levels. Increased ROS generation 
upon the inhibition of OGDH(L) was observed in this 
(Figure 8, SP<0.2 mM) and other studies (reviewed in 
[22, 70]). Much stronger accumulation of succinate in 
T98G vs U87 cells exposed to SP (Figure 7B) suggests 
succinate dehydrogenase to be the SP-stimulated ROS 
source. Changed saturation of the enzyme with succinate 
and NADH, particularly when the malate-aspartate shuttle 
is perturbed and fumarate accumulated, was shown to 
increase the succinate dehydrogenase-dependent ROS 
production in vivo [73]. The conditions are apparently 
stimulated by SP due to excessive 2-oxoglutarate 
transamination with aspartate and tyrosine, on one hand, 
and production of succinate and NADH from GABA 
shunt and branched chain amino acids, on the other hand 
(Figure 6). All these compensatory pathways are less 
expressed in U87 vs T98G cells (Table 2), which may 
better preserve the NAD(P)H levels of U87, compared 
to T98G cells (Figures 1, 3). In addition, as pointed out 
above, the higher abundance of the cystine/glutamate 
antiporter SLC7A11 in cells of higher sensitivity to SP 
(T98G and A549 vs U87 and SK-N-AS, Table 2) may add 
to the NAD(P)H consumption by excessive cystine infux 
through the antiporter (Figure 6). When stimulated by 
glutamate accumulation in cells with inhibited OGDH(L), 
the intracellular cystine will consume NADPH for the 
reduction to cysteine, but further glutathione synthesis 
may be perturbed due to metabolic alterations resulting 
in decreased ATP levels. As a consequence, in spite of the 
ability of the 2-oxoglutarate-utilizing pathways beyond 
OGDH(L) to restore the TCA cycle by generating NADH, 
succinyl-CoA and succinate, perturbed fluxes would be 
anticipated to increase ROS. More NAD(P)H consumption 
for their scavenging would decrease the reducing potential 
of cells, reflected in the MTT and CellTiterBlue assays 
(Figures 1, 3). Disparity in cellular changes in ATP and 
NAD(P)H upon SP action (Figure 4) is well explained by 
the recently shown inhibition of ATP synthase through 
direct binding of 2-oxoglutarate to the enzyme β-subunit 
[74]. Accumulation of 2-oxoglutarate in both T98G and 
U87 cells may explain their similar sensitivity to SP in the 
ATP assay, although the cells react to SP differently in the 
NAD(P)H-based assay due to the reasons discussed above. 
Because the ATP synthase inhibition by 2-oxoglutarate is 
reversible, the observed cell-specific restoration of ATP 
levels during increased SP exposure (Figure 5) may be 
due to compensatory changes in the metabolic network 
addressing the 2-oxoglutarate accumulation.
Analysis of the existing and developing anticancer 
therapies has indicated that drugs have to be developed 
and tested for specific tumors, since drug effects in 
different types of cancer cells are not necessarily the 
same [15, 37]. As demonstrated in our study, synthetic 
compounds with a well-defined molecular mechanism 
of action are of great help in finding solutions for the 
problem. Indeed, different expression of the enzymes of 
the OGDH-dependent metabolic node (Figure 6, Table 2) 
superposed on varied resistance of different cancer cells 
to the OGDH inhibitor SP (Figures 1–5, 7) allows one to 
identify the cell-specific pathways to overcome the drug 
action. Based on this knowledge, combinations of drugs 
could be defined to increase cell specificity of metabolic 
impairment, including that in cancer vs healthy cells.
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MATERIALS AND METHODS
Cell culture
Human Caucasian lung adenocarcinoma (A549), 
human neuroblastoma (SK-NA-S), human astrocytoma 
(MOG-G-CCM), and rat glioma (C6) cell lines were 
obtained from the European Collection of Cell Cultures 
(Center for Applied Microbiology and Research, Salisbury, 
UK). Mouse neuroblastoma N2A and human glioblastoma 
cell lines LN405, T98G, U87, 1321N1 were obtained 
from the European Collection of Cell Cultures or from 
the American Type Culture collection (LGC Standards 
GmbH; Wesel, Germany). The primary cell cultures 
52/11 and 85/13 were obtained from human glioblastoma 
tissue according to established methods [75]. Human 
skin fibroblasts (HSF) were isolated by the outgrowth 
technique from skin explants [76]. Primary rat astrocytes 
and cerebellar granule neurons were obtained from rat 
pups using established protocols [42, 47]. The cultures 
were kept at 37°C in a humidified atmosphere of 95% air 
and 5% CO2. All cell culture media were supplemented 
with 10% FBS, penicillin (100 units/ml) and streptomycin 
(100 μg/ml) (Sigma, St. Louis, MO). Established cell 
culture-specific protocols were used for the culture 
maintenance. MOG-G-CCM and C6 cells were cultured 
in DMEM with 1 g/L glucose, 1 mM pyruvate and 4 mM 
L-glutamine. SK-NA-S cells and HSF were grown in a 
Nutrient mixture F-12 Ham with 3.2 g/L glucose, 0.5 mM 
pyruvate, 2.5 mM L-glutamine. A549 cells were grown 
in a 1:1 mixture of DMEM (D6046, Sigma) and Nutrient 
mixture F-12 Ham (D8437, Sigma). Glioblastoma cells 
were grown in DMEM with 4.5 g/L glucose and 2 mM 
glutamax. Astrocytes were grown in EMEM with 1.3 g/L 
glucose. Neuroblastoma N2A cells were grown in DMEM 
with 4.5 g/L glucose and 4 mM L-glutamine. Cerebellar 
granule neurons were grown in NBM medium with B27 
supplement and 2 mM glutamax.
For the viability and ROS tests, cells were placed 
on transparent 96-well microplates (NUNC, Roskilde, 
Denmark) and white 96-well microplates (Corning 
Incorporated, New York, USA), correspondingly. Primary 
astrocytes and neurons were treated with SP after their 
maturation was complete, i.e. 10-14 days in culture for 
astrocytes [47] and 10-12 days in culture for cerebellar 
granule neurons [42]. Other cells were exposed to SP 24 
h (96-well plates) or 48 h after plating (6-well plates). 
Density of these cells upon seeding was chosen so that 
cells were about 60-70% confluent at the beginning of 
the experiment, not reaching confluence by the end of 
incubation with SP.
Cell viability/growth assay
MTT (Sigma Chemicals, St. Louis, MO, USA), 
CellTiterBlue and CellTiterGlo reagents (Promega, 
Mannheim, Germany) were employed to test cellular 
viability. If not indicated otherwise, serial dilutions of 
SP (0.01-20 mM) were added to cells in fresh culture 
media. During the medium exchange before the SP 
addition, glioblastoma cells were brought to DMEM with 
1 g/L glucose, 1 mM pyruvate and 2 mM glutamax. The 
influence of SP in minimal medium was studied in the 
earlier employed buffered salt solution, pH 7.4, containing 
135 mM NaCl, 5 mM KCl, 5 mM glucose, 1.8 mM 
CaCl2, 0.01 mM glycine, 20 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) [42].
Viability of the cell lines was assessed after 96 h of 
exposure to SP by using the MTT method in which the 
yellow tetrazolium salt 3-(4,5-dimethylthiazole-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) is reduced by viable 
cells at the expense of their NAD(P)H to purple formazan 
crystals. Tumor cells were incubated for 3 h with MTT 
solution (5 mg/ml). Formazan crystals were solubilized 
overnight in SDS buffer (10% SDS in 0.01 N HCl) and 
the product was quantified spectrophotometrically by 
measuring absorbance at 570 nm using an Infinite M200 
Pro microplate reader (Tecan, Männedorf, Switzerland). 
When viability of N2A cells was assessed after 5 h 
of exposure to SP, a modification of the MTT method 
described above was applied, adapted to the shorter time 
of the experiment. In this case, cells were incubated 
for 3 h with MTT solution (0.15 mg/ml), followed by 
the solubilization of formazan crystals during 5 min in 
isopropanol/HCl solution (20 ml of isopropanol and 
0.12 ml of 12 N HCl). The product was quantified 
spectrophotometrically by measuring absorbance at 
580 nm using a GLOMAX Multi+ detection system of 
Promega (Madison, WI, USA). In good accordance with 
the published application of both MTT procedures, we 
did not notice any significant change in the estimation of 
the N2A viability by the two MTT procedures applied. 
Viability of glioblastoma cells was also assessed using 
CellTiterBlue and CellTiterGlo reagents (Promega) 
according to the manufacturer’s instructions with 
modifications described earlier [42]. To exclude a possible 
influence of the experimental medium components on the 
ATP assay system, the incubation media were exchanged 
for the SP-free ones. That is, the cell lysis in ATP assay 
was performed by substitution of the incubation media for 
50 μL of the CellTiterGlo reagent diluted 1:1 with HBSS. 
Luminescence was detected after 10 min incubation. 
CellTiterBlue assay was earlier shown not to be affected 
by SP [42], owing to which 20 μL of the CellTiterBlue 
reagent were added directly into 100 μL of the media per 
well. Fluorescence was detected after 1 h incubation with 
the CellTiterBlue reagent.
Measurement of ROS production
ROS were assayed by chemiluminescence of 
lucigenin after its reaction with superoxide anion radical 
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according to [77]. After 5 h incubation of N2A cells with 
SP, the incubation medium was exchanged for 100 μL of 
cold phosphate-buffered saline (PBS) with 2 μM CaCl2 
and 0.08 μM lucigenin, and chemiluminescence was 
measured, using the GLOMAX Multi+ detection system 
of Promega (Madison, WI, USA). The measurements were 
done right after addition of lucigenin, as repeated assays 
after 10 min incubation in the presence of lucigenin did not 
increase the luminescence. As a blank, chemiluminescence 
in control wells was used, where no cells were present, 
but the cell growth medium was exchanged for PBS with 
added calcium and lucigenin.
Glutamate and glutamine assays
Neuroblastoma glutamate was assayed enzymatically 
using a commercially available preparation of bovine liver 
glutamate dehydrogenase (Sigma–Aldrich, Taufkirchen, 
Germany) as described previously [47]. Glutamate 
dehydrogenase (0.05 mg/mL, 45 units/mg) was added to 
0.1 M Tris/HCl buffer, pH 8.0, containing 1.5 mM NAD+ 
and 0.02 mL of cell lysate. Quantification of glutamate was 
done from the maximal increase in optical density at 340 
nm, using the molar extinction coefficient of NADH 6220 
M−1 cm−1, based on equimolar production of NADH from 
glutamate in the glutamate dehydrogenase reaction. The 
cells on 6-well plates were exposed to 0.01-2.5 mM SP 
for 5 h at 37 °C in the buffered salt solution [42], pH 7.4, 
containing 135 mM NaCl, 5 mM KCl, 5 mM glucose, 1.8 
mM CaCl2, 0.01 mM glycine, 20 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES). After the incubation 
was complete, the plates were put on ice, medium was 
removed, the cells were washed twice with cold PBS and 
extracted with cold water solution containing 40% methanol 
supplemented with 0.12% acetic acid. The plates were 
slowly shaken for one hour. Cells were scraped, collected in 
0.75 ml tubes and centrifuged at 6200 g for 15 min at 4°C. 
The pellets were stored at –20°C until protein analysis.
Neuronal glutamate and glutamine content was 
assayed by the GC-MS procedure described below under 
Metabolic profiling. The neuron-specific modifications for 
the extract preparation were as employed before [42].
Metabolic profiling
1x106 cells were grown on Petri dishes for 24 hours. 
Then the growth medium was changed to DMEM with 
1g/L glucose containing 10% FBS, antibiotics, 2 mM 
glutamax with or without 0.5 mM SP. After an incubation 
time of 24 hours cells were washed once with ice-cold 
PBS, and subsequently the methanol extraction and 
metabolic profiling were performed according to [42]. 
Metabolites of both cell lines were extracted in 2 ml of 
ice-cold methanol containing 0.05 mM ribitol as internal 
standard for the relative quantification of metabolite 
abundance [78]. After centrifugation, the supernatant was 
collected and stored at -80 °C until the analysis. The pellet 
was used for protein quantification according to [79]. 
Polar and non-polar phases of the extracts were separated 
by addition of water and chloroform. Aliquots of 0.3 
mL of the polar phase (upper phase) were dried using a 
vacuum centrifugation concentrator (Eppendorf, Hamburg, 
Germany). Sample derivatization was carried out 
according to [78]. 40 μl of methoxyamine hydrochloride 
(CAS 593-56-6, Sigma, Munich, Germany) dissolved 
at 20 mg/mL in pure pyridine (CAS 110-86-1, Merck, 
Darmstadt, Germany) was added to the dried samples and 
maintained at 37°C for 2h. After a rapid centrifugation, 
70 μl of N-methyl-N-(trimethylsilyl)-trifluoroacetamide 
(MSTFA, CAS 24589-78-4, Macherey & Nagel, Düren, 
Germany) were added and the samples were vortex mixed 
and maintained at 37°C for additional 30 min. The tubes 
were centrifuged and 70 μl were transferred to glass vials 
in order to be run in GC-MS. The samples were analyzed 
by GC-MS using two technical replicates per sample and 
where necessary were injected at two different dilutions 
in order to accurately measure both high and relatively 
low abundant metabolites. The chromatograms and mass 
spectra were evaluated by Chroma TOF 1.6 (Leco, St 
Joseph, MI) and TagFinder 4.0 [80] and metabolites were 
identified by comparison with mass spectral database 
[81, 82]. The GC-MS metabolite determinations were 
normalized to ribitol and protein content (μg) and 
presented as fold-changes to the respective controls. The 
metabolic profiles of U87 and T98G cells under control 
conditions were compared by normalization of the T98G 
metabolite levels to those in U87 cells. For the heat 
map visualisation the normalized values were Log(2) 
transformed and the heat map was created using multiple 
array view (MeV)® software (http://www.tm4.org/mev). 
Five independent extracts for each cell line (control and 
SP-treated) were analysed. Statistical significance of the 
differences was analysed by Student’s t-test at p < 0.05.
Protein assay
Total cellular protein was determined by dissolving 
the cell pellet in 20 μL of 1 M KOH at 37°C for 60 min, 
followed by analysis with a BSA Protein Assay Kit 
(Thermo Scientific, Prod # 23232).
Analysis of transcriptomics data
Transcriptomics data for the full annotated genes of 
interest were extracted from the NCBI Gene Expression 
Omnibus (GEO) database using Microarray Retriever 
[83]. The program output presents the data as an excel file 
of sorted genes with detailed information on each gene. 
For the four cell lines analyzed (A549, SK-N-AS, T98G 
and U87) global transcriptomics data were available. 
The following datasets were used in our analysis: for 
SK-N-AS - GSM302678, GSM302679, GSM302680, 
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GSM302681, GSM1086183, GSM1086184, GSM558078, 
GSM558079, GSM558080, GSM692855; for A549 - 
GSM1414981, GSM1414982, GSM1414983, GSM94306, 
GSM1122064; for T98G - GSM96274, GSM96275, 
GSM96276, GSM211868; for U87 - GSM862922, 
GSM862923, GSM862924, GSM1280363, GSM1280365. 
Transcript values were grouped for averaging according 
to their coincidence, which depended on the microarray 
and evaluation algorithm used. The coincidence was 
high (StDev < 20%) in different experiments which used 
the same Affymetrix platform and validation algorithm. 
Using other microarrays (Agilent or different platforms 
of Affymetrix) and/or evaluation algorithms could result 
in transcript signals which differ far beyond StDev < 
20%. Our comparison of cell lines was therefore based 
on the range of relative transcript values obtained from n 
coinciding experiments. The values were normalized to 
the level of expression of 2-oxoglutarate dehydrogenase in 
the same experiment(s). The expression of 2-oxoglutarate 
dehydrogenase was calculated as the sum of the signals 
corresponding to expression of the two catalytically 
competent isoforms of the enzyme, coded by the OGDH 
and OGDHL genes [43, 44].
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